Informações de Eli Lilly and Co

Mais detalhes de Eli Lilly and Co Empresa

Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).



Código da empresaLLY

Nome da EmpresaEli Lilly and Co

Data de listagemJul 09, 1970

CEOMr. David A. (Dave) Ricks

Número de funcionários47000

Tipo de títulosOrdinary Share

Fim do ano fiscalJul 09

EndereçoLilly Corporate Ctr

CidadeINDIANAPOLIS

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal46285

Telefone13172762000

Sitehttps://www.lilly.com/

Código da empresaLLY

Data de listagemJul 09, 1970

CEOMr. David A. (Dave) Ricks

Executivos da empresa Eli Lilly and Co



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. J. Erik Fyrwald

Independent Director

74.35K

+0.02%

Ms. Anne E. White

Executive Vice President, President - Lilly Neuroscience

74.21K

+13.18%

Mr. Patrik Jonsson

Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA

54.13K

+20.12%

Mr. Edgardo Hernandez

Executive Vice President, President - Manufacturing Operations

39.73K

-0.04%

Mr. Ilya Yuffa

Executive Vice President, President of Lilly International

26.26K

-4.54%

Ms. Anat Hakim

Executive Vice President, General Counsel, Secretary

25.66K

-41.06%

Dr. Katherine Baicker, Ph.D.

Independent Director

23.16K

+0.62%

Mr. Diogo Rau

Executive Vice President, Chief Information and Digital Officer

19.72K

+77.63%

Mr. Lucas E. Montarce

Chief Financial Officer, Executive Vice President

14.69K

+5.12%

Mr. Eric Dozier

Executive Vice President, Chief People Officer

9.84K

+15.72%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. J. Erik Fyrwald

Independent Director

74.35K

+0.02%

Ms. Anne E. White

Executive Vice President, President - Lilly Neuroscience

74.21K

+13.18%

Mr. Patrik Jonsson

Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA

54.13K

+20.12%

Mr. Edgardo Hernandez

Executive Vice President, President - Manufacturing Operations

39.73K

-0.04%

Mr. Ilya Yuffa

Executive Vice President, President of Lilly International

26.26K

-4.54%

Ms. Anat Hakim

Executive Vice President, General Counsel, Secretary

25.66K

-41.06%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Diabetes-Mounjaro

5.20B

33.42%

Diabetes-Zepbound

3.38B

21.73%

Oncology-Verzenio

1.49B

9.57%

Diabetes-Trulicity

1.09B

7.02%

Diabetes-Other Diabetes

980.40M

6.30%

Outro

3.42B

21.95%

Por RegiãoUSD

Nome

Receita

Proporção

U.S.

10.81B

69.51%

Europe

2.57B

16.55%

Other foreign countries

1.18B

7.60%

Japan

521.00M

3.35%

China

465.90M

2.99%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Diabetes-Mounjaro

5.20B

33.42%

Diabetes-Zepbound

3.38B

21.73%

Oncology-Verzenio

1.49B

9.57%

Diabetes-Trulicity

1.09B

7.02%

Diabetes-Other Diabetes

980.40M

6.30%

Outro

3.42B

21.95%

Distribuição de ações

Atualizado em: sex, 16 de mai

Investidores

Tipos de investidores

Investidores

Proporção

Lilly Endowment, Inc.

9.94%

The Vanguard Group, Inc.

8.56%

PNC Investments LLC

5.40%

BlackRock Institutional Trust Company, N.A.

4.37%

State Street Investment Management (US)

3.65%

Outro

68.08%

Investidores

Proporção

Lilly Endowment, Inc.

9.94%

The Vanguard Group, Inc.

8.56%

PNC Investments LLC

5.40%

BlackRock Institutional Trust Company, N.A.

4.37%

State Street Investment Management (US)

3.65%

Outro

68.08%

Tipos de investidores

Investidores

Proporção

Investment Advisor

45.73%

Investment Advisor/Hedge Fund

18.43%

Foundation

10.00%

Research Firm

1.97%

Bank and Trust

1.90%

Pension Fund

1.89%

Insurance Company

1.49%

Sovereign Wealth Fund

1.29%

Hedge Fund

0.92%

Outro

16.38%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

5755

792.25M

83.78%

-5.37M

2025Q2

5717

798.76M

84.28%

+2.87M

2025Q1

5710

800.38M

84.44%

+5.04M

2024Q4

5528

795.43M

83.87%

+627.51K

2024Q3

5177

793.57M

83.49%

-5.03M

2024Q2

5068

795.80M

83.72%

-2.01M

2024Q1

4916

795.04M

83.62%

-6.22M

2023Q4

4670

799.46M

84.21%

-2.37M

2023Q3

4354

800.21M

84.30%

-1.19M

2023Q2

4197

799.48M

84.22%

-4.32M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Lilly Endowment, Inc.

95.49M

10.09%

-243.99K

-0.25%

Sep 30, 2025

The Vanguard Group, Inc.

80.05M

8.46%

+1.17M

+1.49%

Jun 30, 2025

PNC Investments LLC

51.08M

5.4%

-9.49K

-0.02%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

41.30M

4.36%

-168.44K

-0.41%

Jun 30, 2025

State Street Investment Management (US)

34.51M

3.65%

+69.02K

+0.20%

Jun 30, 2025

Fidelity Management & Research Company LLC

24.36M

2.57%

-2.82M

-10.39%

Jun 30, 2025

Capital Research Global Investors

20.76M

2.19%

+5.01M

+31.81%

Jun 30, 2025

Geode Capital Management, L.L.C.

18.13M

1.92%

-397.62K

-2.15%

Jun 30, 2025

Capital World Investors

17.63M

1.86%

-748.08K

-4.07%

Jun 30, 2025

T. Rowe Price Associates, Inc.

15.69M

1.66%

-2.29M

-12.75%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

Defiance Daily Target 2X Long LLY ETF

56.78%

iShares U.S. Pharmaceuticals ETF

22.3%

VanEck Pharmaceutical ETF

19.92%

Roundhill GLP-1 & Weight Loss ETF

15.25%

Harbor Health Care ETF

15.17%

Health Care Select Sector SPDR Fund

12.02%

Proshares Ultra Health Care

12%

iShares U.S. Healthcare ETF

11.64%

Fidelity MSCI Health Care Index ETF

10.6%

Direxion Daily Healthcare Bull 3X Shares

9.65%

Ver Mais

Defiance Daily Target 2X Long LLY ETF

Proporção56.78%

iShares U.S. Pharmaceuticals ETF

Proporção22.3%

VanEck Pharmaceutical ETF

Proporção19.92%

Roundhill GLP-1 & Weight Loss ETF

Proporção15.25%

Harbor Health Care ETF

Proporção15.17%

Health Care Select Sector SPDR Fund

Proporção12.02%

Proshares Ultra Health Care

Proporção12%

iShares U.S. Healthcare ETF

Proporção11.64%

Fidelity MSCI Health Care Index ETF

Proporção10.6%

Direxion Daily Healthcare Bull 3X Shares

Proporção9.65%

Dividendo



Um total de 18.06B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Dec 09, 2024

LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025

Feb 14, 2025

Mar 10, 2025

Feb 14, 2025

Oct 28, 2024

LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024

Nov 15, 2024

Dec 10, 2024

Nov 15, 2024

Jun 24, 2024

LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024

Aug 15, 2024

Sep 10, 2024

Aug 15, 2024

May 06, 2024

LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024

May 16, 2024

Jun 10, 2024

May 15, 2024

Dec 08, 2023

LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024

Feb 15, 2024

Mar 08, 2024

Feb 14, 2024

Nov 01, 2023

LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023

Nov 15, 2023

Dec 08, 2023

Nov 14, 2023

Jun 26, 2023

LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023

Aug 15, 2023

Sep 08, 2023

Aug 14, 2023

May 01, 2023

LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Jun 09, 2023 going ex on May 12, 2023

May 15, 2023

Jun 09, 2023

May 12, 2023

Dec 12, 2022

LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 10, 2023 going ex on Feb 14, 2023

Feb 15, 2023

Mar 10, 2023

Feb 14, 2023

Oct 17, 2022

LLY.NB Final Cash Dividend of gross USD 0.98 paid on Dec 09, 2022 going ex on Nov 14, 2022

Nov 15, 2022

Dec 09, 2022

Nov 14, 2022

Ver Mais

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados